"With roughly twice as many shares outstanding (somewhat offset by prospect of an expanded label) it should chart a jagged line to the $6 range."

Don't discount the power of the expanded label. There are roughly 9 times as many Type 2's as Type 1's; though not all T2's need insulin. I do think we see a paradigm shift over time and start treating T2's earlier with insulin, especially when needles might not be required.

That expanded label is worth many times more than the label for T1.